Indonesia has opened its first botulinum toxin manufacturing facility, with production scheduled to begin in 2028. The plant represents a significant shift in toxin supply-chain geography, moving production outside traditional hubs in South Korea, China, and the United States. Local production capacity could lower regional costs and reduce import tariffs across Southeast Asia and the broader Indo-Pacific market.
Business & M&A
Indonesia Opens First Botulinum Toxin Plant
New manufacturing capacity set for 2028 production; supply chain diversification ahead.
1-YEAR MOVE
ABBV
▲11.6%
EOLS
▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
| EOLS | Evolus | −15.6% |
Production set to begin in 2028; first toxin plant in Indonesia.
For U.S. and European practices, the near-term impact is minimal—established supply chains through AbbVie, Galderma, Evolus, and Korean manufacturers remain dominant. However, the facility signals accelerating competition in emerging markets and potential pricing pressure as new regional players enter distribution. Practices with international patient bases or supply-chain hedging strategies should monitor whether Indonesian-manufactured toxins eventually reach North American channels.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.